持续血流左心室辅助装置植入后的结局与再入院情况：Heartmate II与Heartware心室辅助装置的比较
Outcomes and Readmissions After Continuous Flow Left Ventricular Assist Device: Heartmate II Versus Heartware Ventricular Assist Device.
作者信息
Tuncer O N, Kemaloğlu C, Erbasan O, Gölbaşı I, Türkay C, Bayezid Ö
机构信息
Erzincan Universıty, Mengücek Gazi Training and Research Hospital, Cardiovascular Surgery Department, Erzincan, Turkey.
Akdeniz Universıty, Faculty of Medicine, Department of Cardiovascular Surgery, Antalya, Turkey.
出版信息
Transplant Proc. 2016 Jul-Aug;48(6):2157-61. doi: 10.1016/j.transproceed.2016.03.056.
INTRODUCTION
Donor organ shortage is still a problem for heart transplantation. Only 10% of patients in waiting list undergo heart transplantation. Over the last 5 years, 2 different continuous flow pumps, the HeartMate II and the HeartWare, have been successful clinically in the alternative treatment of patients with end-stage heart disease.
METHODS
Fifty-five patients underwent left ventricular assist device implantation between 2011 and 2014. Patients were followed on pump support for complications and intraoperative outcomes. Potential device-related complications include infections, bleeding liver dysfunction, renal dysfunction, right ventricular failure, stroke, thromboembolism, gastrointestinal bleeding, and wound infection.
RESULTS
The only preoperative significant difference between groups in the study was age; the Heartmate II group were significantly older than Heartware group. There were no differences in gender, body mass index, or body surface area. The Heartware has a better 1-year survival rate, although the difference was not significant. Patients with Heartmate II had a higher incidence of gastrointestinal bleeding and driveline infection. The Heartware group had a higher incidence of stroke and pump thrombosis.
CONCLUSIONS
The Heartmate II and Heartware are comparable in most respects such as survival, intraoperative features, and major complications.
引言
供体器官短缺仍是心脏移植面临的一个问题。等待名单上只有10%的患者接受了心脏移植。在过去5年里，两种不同的连续流泵，即HeartMate II和HeartWare，在终末期心脏病患者的替代治疗中取得了临床成功。
方法
2011年至2014年间，55例患者接受了左心室辅助装置植入。对患者进行泵支持随访，观察并发症和术中结果。潜在的与装置相关的并发症包括感染、出血、肝功能障碍、肾功能障碍、右心室衰竭、中风、血栓栓塞、胃肠道出血和伤口感染。
结果
研究中两组之间唯一术前的显著差异是年龄；Heartmate II组的年龄明显大于Heartware组。在性别、体重指数或体表面积方面没有差异。Heartware的1年生存率更高，尽管差异不显著。Heartmate II患者胃肠道出血和驱动线感染的发生率更高。Heartware组中风和泵血栓形成的发生率更高。
结论
Heartmate II和Heartware在大多数方面，如生存率、术中特征和主要并发症方面具有可比性。
Zotero 插件